M. Zambetti

发表

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

Roman Rouzier, Lajos Pusztai, J. Ross, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Anton Belousov, Wolfgang Eiermann, M. Cheang, 2014, Clinical Cancer Research.

Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.

G. Bonadonna, P. Valagussa, M. Zambetti, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer.

G. Bonadonna, R. Zucali, P. Valagussa, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence

Elia Biganzoli, Patrizia Boracchi, Danila Coradini, 2010, Cancer science.

Salvage treatments in relapsing resectable breast cancer.

G. Bonadonna, C. Brambilla, P. Valagussa, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer.

G. Bonadonna, C. Brambilla, R. Silvestrini, 1986, NCI monographs : a publication of the National Cancer Institute.

ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.

V. Semiglazov, L. Gianni, P. Valagussa, 2016 .

Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.

G. Bonadonna, M. Daidone, R. Silvestrini, 2000, International journal of cancer.

Treatment of special breast cancer patients

M. Zambetti, A. Moliterni, 2006 .

Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.

A. Marchianò, A. Fasolo, L. Gianni, 2006, Clinical breast cancer.

Long-term sequelae from adjuvant chemotherapy.

G. Bonadonna, P. Valagussa, M. Zambetti, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary

S. Pilotti, M. Zambetti, G. Palo, 1990 .

Role of Bone Scan in Breast Cancer Follow-Up

M. Zambetti, E. Bombardieri, L. Maffioli, 1997, Tumori.

Outcome of Different Timings of Radiotherapy in Implant-Based Breast Reconstructions

M. Zambetti, G. Catanuto, M. Nava, 2011, Plastic and reconstructive surgery.

Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil for Breast Cancer

G. Bonadonna, P. Valagussa, M. Zambetti, 1995 .

Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer.

M. Cronin, S. Shak, J. Baker, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF)

J. Baselga, W. Eiermann, A. Lluch, 2005 .

Intermediate doses of cyclophosphamide alone or following adriamycin in advanced breast cancer. A pilot study.

G. Bonadonna, C. Bartoli, P. Valagussa, 1996, American journal of clinical oncology.

Adjuvant Chemotherapy of Breast Cancer: The Milan Cancer Institute Trials

G. Bonadonna, U. Veronesi, C. Brambilla, 1986 .

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.

A. Brandes, L. Gianni, P. Morandi, 2018, European journal of cancer.

Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer

M. Greco, M. Zambetti, C. Ferraris, 2006 .

Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy. Analysis of drug dosing and toxicity.

G. Bonadonna, R. Weiss, P. Valagussa, 1987, The American journal of medicine.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

Comment to Anderson WF, Jatoi I, Devesa SS: Distinct Breast Cancer Incidence and Prognostic Patterns in the NCI’s SEER Program: Suggesting a Possible Link Between Etiology and Outcome. Breast Cancer Res Treat 90:127–137, 2005

R. Demicheli, G. Bonadonna, M. Greco, 2006, Breast Cancer Research and Treatment.

Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.

D. Coradini, G. Bonadonna, M. Daidone, 1992, Journal of the National Cancer Institute. Monographs.

Timing of Surgery and the Role of Cytoreductive Chemotherapy in Patients with Advanced Ovarian Carcinoma

L. Gianni, M. Zambetti, L. Luciani, 1988, Tumori.

Aminoglutethimide in Postmenopausal Breast Cancer Refractory to Multiple Hormonal and Cytostatic Treatments

G. Bonadonna, C. Brambilla, M. Zambetti, 1987, Tumori.

Nondysgerminomatous tumors of the ovary treated with cisplatin, vinblastine, and bleomycin: long-term results.

S. Pilotti, M. Zambetti, E. Bombardieri, 1992, Gynecologic oncology.

Vinorelbine: An active, non cross-resistant drug in advanced breast cancer. Results from a phase II study

R. Demicheli, A. Caraceni, G. Bonadonna, 2005, Breast Cancer Research and Treatment.

Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.

J. Baselga, W. Eiermann, A. Lluch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitomycin C and Vinblastine in Advanced Refractory Breast Cancer

G. Bonadonna, C. Brambilla, L. Ferrari, 1989, Tumori.

Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy.

G. Bonadonna, C. Brambilla, L. Ferrari, 1991, Seminars in oncology.

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.

G. Viale, L. Gianni, P. Valagussa, 2018, The Lancet. Oncology.

[Locally advanced breast tumors. Role of magnetic resonance in the assessment of response to preoperative therapy and of neoplastic residue before the operation].

M. Zambetti, G. Mariani, G. Trecate, 1998, La Radiologia medica.

Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

J. Baselga, W. Eiermann, V. Semiglazov, 2008 .

A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.

L. Gianni, F. Dalenc, M. Zambetti, 2012, Clinical breast cancer.

Detection of Lewisa antigen in sera of ovarian carcinoma patients by MOv2-MOv8 double-determinant radioimmunoassay

S. Ménard, S. Canevari, M. Zambetti, 1989, The International journal of biological markers.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Chromosome band 17q21 in breast cancer: Significant association between beclin 1 loss and HER2/NEU amplification

M. Gariboldi, M. Pierotti, T. Negri, 2010, Genes, chromosomes & cancer.

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

J. Baselga, W. Eiermann, A. Lluch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

G. Bonadonna, M. Daidone, S. Pilotti, 2005, BMJ : British Medical Journal.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

J. Baselga, M. Climent, W. Eiermann, 2010, The Lancet.

Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process.

R. Demicheli, G. Bonadonna, R. Miceli, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Cis‐platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary

S. Pilotti, M. Zambetti, G. D. De Palo, 1991, Gynecologic oncology.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

J. Baselga, M. Climent, W. Eiermann, 2014, The Lancet. Oncology.

Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’

R. Demicheli, G. Bonadonna, C. Brambilla, 1999, Breast Cancer Research and Treatment.

Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.

G. Bonadonna, L. Gianni, P. Valagussa, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.

G. Bonadonna, P. Valagussa, M. Zambetti, 1995, JAMA.

Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer

B. Győrffy, C. Tacchetti, M. Dugo, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results.

G. Bonadonna, P. Valagussa, M. Zambetti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

G. Bonadonna, C. Brambilla, P. Valagussa, 1995, The New England journal of medicine.

Cell proliferation and outcome following doxorubicin plus CMF regimens in node‐positive breast cancer

G. Bonadonna, M. Daidone, R. Silvestrini, 2000 .

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy

J. Baselga, W. Eiermann, A. Lluch, 2005, Clinical Cancer Research.

Combined sequential approach in locally advanced breast cancer.

G. Bonadonna, R. Zucali, P. Valagussa, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.

J. Baselga, E. Kubista, Li-an Xu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.

L. Gianolli, N. Di Muzio, M. Zambetti, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Local recurrences following mastectomy: support for the concept of tumor dormancy.

R. Demicheli, G. Bonadonna, P. Valagussa, 1994, Journal of the National Cancer Institute.

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

L. Gianni, P. Valagussa, L. Calvo, 2018, JAMA oncology.

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

J. Baselga, W. Eiermann, A. Lluch, 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Shed HER2 extracellular domain in HER2‐mediated tumor growth and in trastuzumab susceptibility

M. Campiglio, S. Ménard, M. Carcangiu, 2010, Journal of cellular physiology.

Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer.

G. Bonadonna, P. Valagussa, M. Zambetti, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel

R. Demicheli, F. Garbagnati, M. Zambetti, 2000, Breast Cancer Research and Treatment.

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.

A. Luini, G. Bonadonna, M. Greco, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant and neoadjuvant treatment of breast cancer.

G. Bonadonna, L. Gianni, P. Valagussa, 2001, Seminars in oncology.

Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.

G. Bonadonna, P. Valagussa, M. Zambetti, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First‐Line Chemotherapy with Intraperitoneal Cisplatin and Intravenous Cyclophosphamide in Ovarian Carcinoma: A Preliminary Report

G. Bonadonna, M. Zambetti, P. Pizzetti, 1989, American journal of clinical oncology.

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

G. Bonadonna, C. Brambilla, L. Ferrari, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy for node-negative breast cancer patients.

G. Bonadonna, P. Valagussa, M. Zambetti, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer

G. Bonadonna, U. Veronesi, C. Brambilla, 2005, Breast Cancer Research and Treatment.

T3b-T4 breast cancer: factors affecting results in combined modality treatments

G. Bonadonna, R. Zucali, P. Valagussa, 1983, Clinical & Experimental Metastasis.

A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer.

Y. Qi, L. Pusztai, W. Symmans, 2012 .

Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy

G. Bonadonna, U. Veronesi, R. Zucali, 1990, Breast Cancer Research and Treatment.

The Milan experience with adjuvant chemotherapy in premenopausal breast cancer.

G. Bonadonna, C. Brambilla, P. Valagussa, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

SURGERY IN ADVANCED BREAST CANCER

G. Bonadonna, P. Valagussa, M. Zambetti, 1988, The Lancet.

Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.

G. Bonadonna, L. Ferrari, P. Valagussa, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer.

M. Zambetti, G. Secreto, P. Ballerini, 1988, European journal of cancer & clinical oncology.

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

Paolo Morandi, Ana Lluch, Patricia Gomez, 2012, Breast Cancer Research and Treatment.

Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group.

G. Bonadonna, P. Valagussa, M. Zambetti, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Y. Qi, C. Sotiriou, B. Haibe-Kains, 2013, Breast Cancer Research.

Coping Mechanisms, Psychological Distress, and Quality of Life Prior to Cancer Genetic Counseling

C. Brombin, M. Zambetti, F. Cugnata, 2018, Front. Psychol..

Activity of vinorelbine (VIN) in advanced breast cancer: Preliminary results of a phase II trial

R. Demicheli, A. Caraceni, G. Bonadonna, 1993 .

Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients

R. Demicheli, G. Bonadonna, F. Garbagnati, 1997, Breast Cancer Research and Treatment.

Antiemetic Activity of Metoclopramide versus Alizapride during Cancer Chemotherapy

M. Zambetti, E. Bajetta, P. Bidoli, 1985, Tumori.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

Locally Advanced Breast Cancer Treated with Primary Chemotherapy: Comparison between Magnetic Resonance Imaging and Pathologic Evaluation of Residual Disease

R Musumeci, M. Zambetti, G. Mariani, 1999, Tumori.